Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + HiDAC in Relapsed/Refractory AML
NCT02768792Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Aug 2016
- Primary completion
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in acute myeloid leukemia (AML), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02768792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768792.